Navigation Links
ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Date:7/29/2008

II clinical development by the end of 2008, and TB-403 (Anti-PlGF). ThromboGenics and its development partner BioInvent, have recently signed a license agreement with Roche for TB-403 worth up to EUR500 million plus royalties. A Phase Ib clinical trial with TB-403 has recently begun in patients with late stage cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact:

ThromboGenics

Chris Buyse, CFO Tel : +32-16-75-13-10

chris.buyse@thrombogenics.com

Citigate Dewe Rogerson

Amber Bielecka/Sylvie Berrebi/David Dible Tel.: +44(0)207-638-9
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
2. ThromboGenics N.V. - Business Update
3. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
4. ThromboGenics Announces 2007 Full Year Results
5. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
8. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
9. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
10. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... COLUMBIA, Md. (PRWEB) February 27, 2015 ... Unified Chromatography system (Nexera UC) can sequentially analyze ... chromatographic separation combined with high-sensitivity detection of targets ... system is designed to fulfill the measurement requirements ... pesticides in food products, drug delivery and search ...
(Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
(Date:2/26/2015)... TORONTO , Feb. 26, 2015 /PRNewswire/ - SQI ... SQIDF), a life sciences company that develops and commercializes ... reported its financial and operational results for the fiscal ... this press release are in Canadian dollars (CAD), unless ... Company continued to win new business from our existing ...
(Date:2/26/2015)... Angeles, CA (PRWEB) February 26, 2015 ... an online demonstration to support life extension technologies and ... 8pm UTC, Universal Coordinated Time, on March 21st 2015, ... the world. , Eric Schulke, Founder of MILE, ... must act with urgency. The Movement for Indefinite Life ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3
... Research Park Center. ZyStor will have labs at the research ... syndicate has drawn a St. Louis niche-market biotech company to ... Milwaukee County Research Park . , ,The company is targeting ... sometimes in young children, using a new technique. , , ...
... Madison, Wis. The University of Wisconsin-Madison plans to ... by June 2006, according to the Division of Information ... that 46 percent of students said they were likely to ... across the campus, DoIT announced on November 2 that it ...
... The University of Wisconsin-Madison Board of Regents has approved ... near UW Hospital and Clinics and the ... spring 2008, awaits approval from the State Building Commission on ... include laboratory facilities, offices, an imaging center and animal quarters. ...
Cached Biology Technology:Wisconsin VCs draw Missouri biotech firm to state 2Wisconsin VCs draw Missouri biotech firm to state 3Wisconsin VCs draw Missouri biotech firm to state 4UW-Madison working to extend wireless access to entire campus 2
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... and reuse of data has become a vital part of ... pace of scientific discovery is not unnecessarily hindered by data ... lab drawers. BioMed Central, a long supporter of ... with LabArchives, LLC to shed further light on science,s "dark ...
... of Adelaide could help protect one of the world,s ... - from extinction. Big leaf mahogany ( Swietenia macrophylla ... It is at risk of extinction in its native ... South America. To better understand how such a threatened ...
... a Simon Fraser University professor and Canada Research Chair ... a hefty financial boost in their efforts to develop ... Institutes of Health (NIH) has awarded the four researchers ... a DNA-based vaccine that Marinieve Montero first conceived of ...
Cached Biology News:Linking and lightening: New partnership connects and reveals dark data 2Pollen can protect mahogany from extinction 2SFU HIV/AIDS vaccine research gets financial boost 2
... Enzyme concentration - 5 units/µL ,• High ... yields ,• Leaves an 'A' overhang ,• ... which exhibits very high activity in primer ... ensure the quality of the enzyme, each ...
... Gold® DNA Polymerase is a chemically modified ... chemical moiety is attached to the enzyme, ... the first ramp of thermal cycling (when ... temperatures), the enzyme is inactive. The result ...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
Request Info...
Biology Products: